- Home
- ANAB vs ALX Comparison
ANAB vs ALX Comparison
Compare ANAB & ALX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANAB | ALX |
|---|---|---|
| Founded | 2005 | 1928 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2015 | 1994 |
Fundamental Metrics
Financial Performance| Metric | ANAB | ALX |
|---|---|---|
| Price | $53.61 | $267.93 |
| Analyst Decision | Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $71.67 | N/A |
| AVG Volume (30 Days) | ★ 818.3K | 15.9K |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 7.20% |
| EPS Growth | ★ 91.02 | N/A |
| EPS | N/A | ★ 0.91 |
| Revenue | ★ $234,603,000.00 | $213,183,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $52.14 | N/A |
| P/E Ratio | ★ N/A | $301.03 |
| Revenue Growth | ★ 157.01 | N/A |
| 52 Week Low | $17.11 | $201.28 |
| 52 Week High | $73.30 | $289.43 |
Technical Indicators
Market Signals| Indicator | ANAB | ALX |
|---|---|---|
| Relative Strength Index (RSI) | 44.82 | 49.14 |
| Support Level | $52.32 | $266.91 |
| Resistance Level | $57.70 | $281.56 |
| Average True Range (ATR) | 4.55 | 6.34 |
| MACD | -0.98 | -1.37 |
| Stochastic Oscillator | 24.72 | 22.56 |
Price Performance
Historical ComparisonAbout ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About ALX Alexander's Inc.
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing, and redeveloping its properties. It has five properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City, which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.